Guideline Panel Meeting: Overactive Bladder (2023)
Clinical Practice Guidelines Panel Meeting. Panelists will meet for two days to evaluate the evidence report and craft statements for the AUA guideline based on this evidence. By the end of the two days, the panel will come to a consensus on the group of evidence-based statements and supporting text that will form the new AUA Guideline on Overactive Bladder.
Target Audience
This activity is limited to OAB Guidelines Panel Members only.
Learning Objectives
After completing this activity, participants will be able to:
- Analyze the latest scientific evidence for the diagnosis and management of OAB.
- Recommend appropriate diagnostic and treatment options for OAB.
- Apply improved critical thinking skills to medical literature reviews.
Sunday, October 1, 2023
10:00 Welcome and Introductions Anne Cameron, MD
Ariana Smith, MD
10:10 COI Policy & Panel Disclosures Leila Rahimi, MHS
10:20 Timeline and Schedule Leila Rahimi, MHS
10:30 Evidence Report Presentation Lesley Souter, PhD
11:30 Statement Review and Discussion
11:30 – 1:00 Group One Drs. Ginsberg & Dielubanza
1:00 Break
1:30 – 3:00 Group Two Drs. Rovner & Takacs
3:00 – 4:30 Group Three Drs. Suskind & Reynolds
4:30 Meeting Adjourned
Monday, October 2, 2023
10:00 Statement Review and Discussion
10:00 -11:30 Group Four Drs. Enemchukwu & Welk
11:30 – 1:00 Group Five Dr. Chung
1:00 Break
1:30 Statement Review and Discussion
1:30 – 3:00 Group Six Drs. Helfand & Linder
3:00 Next Steps Leila Rahimi, MHS
3:30 Meeting Adjourned
The Overactive Bladder (OAB) Guidelines Panel have the following disclosures.
Name | Company Name | Relationship Type | Financial | End Date |
Chung, Doreen Eleanor | SpineX | Scientific Study or Trial | No | Current |
Chung, Doreen Eleanor | Abbvie | Scientific Study or Trial | No | Current |
Dielubanza, Elodi J. | None | |||
Enemchukwu, Ekene | Urovant | Scientific Study or Trial | No | Current |
Enemchukwu, Ekene | Avation | Scientific Study or Trial | No | 12/01/2022 |
Enemchukwu, Ekene | Boston Scientific | Consultant or Advisor | Yes | Current |
Enemchukwu, Ekene | Abbvie | Consultant or Advisor | Yes | 06/08/2022 |
Enemchukwu, Ekene | Abbvie | Scientific Study or Trial | No | Current |
Enemchukwu, Ekene | Valencia | Other-Chair of DSMB | Yes | Current |
Enemchukwu, Ekene | Journal of Urology | Other-Editorial Board | No | Current |
Enemchukwu, Ekene | NIH NIDDK | Other-Research Funding | No | Current |
Enemchukwu, Ekene | Neurourology and Urodynamics | Other-Editorial Board | No | Current |
Ginsberg, David Alan | Procept | Scientific Study or Trial | No | 09/20/2022 |
Ginsberg, David Alan | Neurourology and Urodynamics | Health Publishing | No | Current |
Ginsberg, David Alan | Society of Urodynamics, Female Pelvic Medicine & U | Leadership Position | No | Current |
Ginsberg, David Alan | Urovant | Consultant or Advisor | Yes | 12/02/2021 |
Ginsberg, David Alan | Urovant | Scientific Study or Trial | No | 12/31/2022 |
Ginsberg, David Alan | Caldera | Consultant or Advisor | Yes | Current |
Ginsberg, David Alan | Avation | Consultant or Advisor | Yes | 09/17/2022 |
Ginsberg, David Alan | Medtronic | Meeting Participant or Lecturer | Yes | 09/20/2022 |
Helfand, Brian T. | Exact Sciences | Meeting Participant or Lecturer | Yes | 01/01/2023 |
Helfand, Brian T. | Ambry | Consultant or Advisor | Yes | 12/31/2021 |
Helfand, Brian T. | Exact Sciences | Other-Researcher | Yes | 07/31/2022 |
Helfand, Brian T. | Blue Earth Diagnostics | Meeting Participant or Lecturer | Yes | Current |
Helfand, Brian T. | Blue Earth Diagnostics | Consultant or Advisor | Yes | 07/31/2022 |
Helfand, Brian T. | GoPath | Consultant or Advisor | Yes | Current |
Helfand, Brian T. | Procept | Consultant or Advisor | Yes | Current |
Helfand, Brian T. | NIDDK NIH | Scientific Study or Trial | No | Current |
Helfand, Brian T. | Urovant | Scientific Study or Trial | No | 06/01/2023 |
Helfand, Brian T. | Angiodynamics | Scientific Study or Trial | No | Current |
Helfand, Brian T. | Zenflow | Scientific Study or Trial | No | 12/31/2023 |
Helfand, Brian T. | Olympus | Scientific Study or Trial | No | 01/31/2024 |
Linder, Brian J. | Medtronic | Consultant or Advisor | Yes | 04/02/2022 |
Linder, Brian J. | Medtronic | Scientific Study or Trial | No | Current |
Linder, Brian J. | Medtronic | Scientific Study or Trial | No | Current |
Linder, Brian J. | Neurourology and Urodyanmics | Other-Editorial Board member | No | Current |
Linder, Brian J. | National Institutes of Health | Scientific Study or Trial | No | Current |
Pelletier Cameron, Anne K. | Medtronic | Scientific Study or Trial | No | 05/25/2022 |
Pelletier Cameron, Anne K. | Axonics | Consultant or Advisor | Yes | 02/05/2022 |
Pelletier Cameron, Anne K. | Wiley | Health Publishing | Yes | 12/31/2025 |
Pelletier Cameron, Anne K. | Springer | Health Publishing | Yes | Current |
Pelletier Cameron, Anne K. | NIDDK | Scientific Study or Trial | No | Current |
Pelletier Cameron, Anne K. | SUFU | Leadership Position | No | Current |
Pelletier Cameron, Anne K. | SWIU | Leadership Position | No | 05/15/2024 |
Reynolds, William Stuart | NIH NIDDK | Other-Research Grant | Yes | Current |
Reynolds, William Stuart | SUFU | Leadership Position | No | Current |
Reynolds, William Stuart | SUFU | Other-Research Grant | No | Current |
Reynolds, William Stuart | Neurourology & Urodynamics | Health Publishing | No | Current |
Rovner, Eric Scott | Allergan | Consultant or Advisor | Yes | Current |
Rovner, Eric Scott | Medtronics | Consultant or Advisor | Yes | Current |
Rovner, Eric Scott | NextMed | Owner (Medical Pratice/ESWL Company) | Yes | Current |
Rovner, Eric Scott | Urovant | Scientific Study or Trial | Yes | Current |
Rovner, Eric Scott | Bluewind | Consultant or Advisor | Yes | Current |
Rovner, Eric Scott | Hologix | Consultant or Advisor | Yes | Current |
Rovner, Eric Scott | uromedica | Scientific Study or Trial | Yes | 04/04/2023 |
Rovner, Eric Scott | Valencia | Consultant or Advisor | Yes | Current |
Rovner, Eric Scott | Convatec | Scientific Study or Trial | No | Current |
Rovner, Eric Scott | Avation | Consultant or Advisor | Yes | Current |
Rovner, Eric Scott | Boston Scientific | Meeting Participant or Lecturer | Yes | Current |
Rovner, Eric Scott | Axonics | Consultant or Advisor | Yes | Current |
Rovner, Eric Scott | EG-427 | Consultant or Advisor | Yes | Current |
Rovner, Eric Scott | Ironwood | Scientific Study or Trial | Yes | Current |
Rovner, Eric Scott | National Association for Continence | Leadership Position | No | Current |
Rovner, Eric Scott | Synapse IC | Consultant or Advisor | Yes | Current |
Rovner, Eric Scott | Viveve | Consultant or Advisor | Yes | 04/04/2023 |
Rovner, Eric Scott | Urocure | Stock Option | Yes | Current |
Smith, Ariana L. | SUFU | Leadership Position | No | Current |
Smith, Ariana L. | Wiley Neurolurology and Urodynamics | Leadership Position | No | Current |
Smith, Ariana L. | NIDDK | Scientific Study or Trial | Yes | Current |
Smith, Ariana L. | NICHD | Scientific Study or Trial | Yes | Current |
Smith, Ariana L. | Pennsylvania Department of State | Scientific Study or Trial | Yes | Current |
Suskind, Anne M. | Flume | Consultant or Advisor | Yes | Current |
Suskind, Anne M. | Solv Wellness | Meeting Participant or Lecturer | Yes | 04/01/2022 |
Suskind, Anne M. | SUFU | Leadership Position | No | Current |
Suskind, Anne M. | Neurourology and Urodynamics | Health Publishing | No | Current |
Suskind, Anne M. | Journal of Urology | Health Publishing | Yes | Current |
Suskind, Anne M. | Urology Practice | Health Publishing | No | Current |
Suskind, Anne M. | Society of Women in Urology | Leadership Position | No | Current |
Suskind, Anne M. | AHRQ | Consultant or Advisor | No | 02/01/2026 |
Suskind, Anne M. | Internatinoal Continence Society (ICS) | Leadership Position | No | 09/01/2023 |
Takacs, Elizabeth Broghammer | Medtronic | Scientific Study or Trial | Yes | Current |
Takacs, Elizabeth Broghammer | North Central Section of the AUA | Leadership Position | No | Current |
Welk, Blayne Kaili | BD | Consultant or Advisor | Yes | 03/31/2022 |
Welk, Blayne Kaili | Zenflow | Scientific Study or Trial | No | Current |
AUA Staff have nothing to disclose.
All relevant financial relationships have been mitigated.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity for a maximum of 11.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 11.00 AMA PRA Category 1 Credit™
- 11.00 Non-Physician Participation